Medicare Drug Price Negotiations: Trulicity, Rexulti Targets
- The Trump administration announced on Tuesday, november 25, 2025, that 15 additional drugs will be subject to medicare price negotiation, marking the first time treatments administered in doctor's...
- Previously, only retail drugs covered by Medicare Part D were eligible for price negotiation during the first two rounds.
- According to STAT News, this is the third round of drugs selected for price negotiation.
Trump Administration Adds 15 Drugs to Medicare Price Negotiation List
The Trump administration announced on Tuesday, november 25, 2025, that 15 additional drugs will be subject to medicare price negotiation, marking the first time treatments administered in doctor’s offices are included. This is the third round of drugs selected for negotiation, and the first to include those covered under Medicare Part B.
Expanding Negotiation to Part B Drugs
Previously, only retail drugs covered by Medicare Part D were eligible for price negotiation during the first two rounds. The inclusion of Part B drugs represents a notable expansion of the program established by the Inflation Reduction Act. The negotiated prices for these 15 drugs will go into effect in 2028.
According to STAT News, this is the third round of drugs selected for price negotiation.
Administration’s Stance on Negotiation
Despite the program’s implementation, the Trump administration has publicly minimized the Medicare price negotiation program, even as it continues to execute the law. This stance contrasts with some Republican opposition to government intervention in drug pricing.